Louise Frederika Kooij Sells 65,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00. Following the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

NewAmsterdam Pharma Trading Down 3.1%

NASDAQ:NAMS opened at $35.42 on Friday. The stock has a market cap of $4.14 billion, a P/E ratio of -19.79 and a beta of 0.02. The stock has a 50 day simple moving average of $33.25 and a 200 day simple moving average of $34.20. NewAmsterdam Pharma Company N.V. has a 1-year low of $16.95 and a 1-year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. The firm had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. As a group, sell-side analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.76 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on NAMS. Needham & Company LLC lifted their price target on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Guggenheim lifted their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Finally, Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.00.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its holdings in NewAmsterdam Pharma by 84.4% in the 1st quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock valued at $27,115,000 after acquiring an additional 387,698 shares in the last quarter. Stempoint Capital LP raised its holdings in NewAmsterdam Pharma by 147.1% in the 1st quarter. Stempoint Capital LP now owns 180,658 shares of the company’s stock valued at $5,783,000 after acquiring an additional 107,552 shares in the last quarter. California State Teachers Retirement System raised its holdings in NewAmsterdam Pharma by 34.9% in the 1st quarter. California State Teachers Retirement System now owns 54,329 shares of the company’s stock valued at $1,739,000 after acquiring an additional 14,053 shares in the last quarter. Maverick Capital Ltd. raised its holdings in NewAmsterdam Pharma by 15.4% in the 1st quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock valued at $69,987,000 after acquiring an additional 292,176 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in NewAmsterdam Pharma by 35.6% in the 1st quarter. Sei Investments Co. now owns 55,637 shares of the company’s stock valued at $1,781,000 after acquiring an additional 14,597 shares in the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.